We aim to develop a novel in silico platform, the Artificial Intelligence Digital Twin, for personalized healthcare. Our technology diverges from traditional diagnostic and treatment methodologies that operate on a one-size-fits-all basis, and typically focus on generalized patient data and static, “visualization” models of disease progression. The AI digital twin breaks through these barriers by offering dynamic, real-time, holistic patient-specific models instead, thus setting new standards for patient care.
The AI digital twin is constructed using mathematical modeling and computer simulations that encompass hierarchical dynamic connections across all bodily levels—from genes, proteins, cells, tissues, organs, organ systems, to the entire human body for individual patients. Powered by an exclusive amalgamation of the latest AI algorithms, advanced systems computational biology, and mathematical modeling techniques, it is consistently refined to align with the newest, rapidly evolving biomedical research, ensuring the methodology remains cutting-edge. When complete, the AI digital twin will provide:
· Patient’s comprehensive health evaluation: an in silico framework for dynamic, real-time studies of otherwise inaccessible (patho)physiological processes, enhancing the understanding of mechanisms, and the ability to predict, diagnose, and manage individual patients' medical conditions with remarkable accuracy.
· Personalized holistic healthcare: an expedient unified framework for clinicians to effectively exchange information and to make joint decisions regarding patient care and management. This solves the current critical issue in modern medicine of treating a patient’s disease, rather than providing comprehensive care by treating the patient as a whole.
· Streamlined healthcare workflow: the capability to revolutionize the standard of care by enabling continuous health monitoring, assessment, and notification based on the real-time analysis of ongoing physiological processes.
· Personalized treatment: assistance in designing a rationalized treatment strategy for each patient depending on their individual biomedical profile; identification and validation of appropriate drugs tailored to the patient’s individual biomedical profile, thus selecting optimal therapeutic treatment; eliminate short and long-term potential side effects of administered drugs, which could often be detrimental to patient’s life.
The Market Opportunity
ABS Technologies LLC is strategically positioned to capitalize on the global trend towards personalized and predictive healthcare. The Total Available Market (TAM) for AI in healthcare is projected to grow from $32.3 billion in 2024 to $208.2 billion by 2030. Within this trend, the AI digital twin technology targets the rapidly increasing Serviceable Available Market (SAM) for healthcare digital twins, which is expected to rise from $1.6 billion in 2023 to $21.1 billion by 2028. Aiming to capture a 1-2% share of the SAM at market entry and targeting a 3-5% share at maturity, we highlight sustainable growth and an attractive market opportunity in the future.
Our target segments include practicing physicians seeking enhanced patient care through personalized treatments, biotech firms aiming to reduce time-to-market for new therapies, pharmaceutical companies focused on streamlining R&D processes, and academic and research institutions such as medical and pharmacy schools aiming to advance their teaching and research. The common primary pain point across these segments is the lack of individual patient health models that accurately predict disease development and progression, and treatment responses. By addressing these needs, ABS Technologies LLC not only aligns with but also propels market trends towards more digitalized and personalized healthcare solutions. Our technology is set to transform patient care, personalized treatment, biomedical research, and training the new generation of medical doctors. This strategic market positioning provides a competitive role within the digital transformation of the healthcare sector.
The company was founded on 12/09/2022 by Drs. R. N. Miftahof and A. A. Hermann and registered with the state of Iowa, business number 732672. The company’s office is located at 85 Weston St., North Liberty, IA 52317.
Roustem N. Miftahof, an Emeritus Professor with doctorates in Medicine, Applied Mathematics, and Technical Sciences is internationally recognized as a pioneer in computational systems biology and medicine. He has authored and co-authored numerous books and academic papers in these fields. His illustrious career spans academia and industry in Europe, the Far East, the Middle East, and North America. Presently, he serves as a Research Professor at Hamburg University of Technology, Germany, where his focus lies on the mathematical modeling of the human brain-stomach axis.
Dr. Alexander Hermann holds a Ph.D. in engineering and continuum mechanics. He specializes in computer simulations, heat and mass transfer modeling, numerical investigations into human body-implants interactions. Dr. A. Hermann holds an MBA degree from the Northern Institute of Technology Management, Hamburg, Germany. Since 2022, Alexander has been acknowledged as a University Innovation Fellow at Stanford University's doctoral school. He has coordinated and led various training sessions and workshops focused on Innovation and Design Thinking, fostering the development of innovative thought processes for both graduate and undergraduate students.